Osimertinib With Savolitinib Demonstrates Stronger Efficacy Than Osimertinib Alone in Patients Who Do Not Respond Well to EGFR-TKIs Therapy

The combination of osimertinib and savolitinib showed clinically meaningful improvement in objective response rate compared to osimertinib alone, according to research presented today at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer. SAN…